drugset / Trial / NCT04277247
Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
To study the effects of Botulinum toxin type A (BTXA) in the treatment of foot dystonia-associated pain in Parkinson's disease
Timeline
- Start
- 2021-01-12
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 100 iu | Intramuscular |